Tempo Therapeutics Raises $14.5 Million To Advance Regenerative Tissue Technology Toward Commercialization

{
  "signal_id": "49d66914-0ee3-a1c3-cbaf-d4afb7dfda7e",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-09-19T12:22:36+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://pulse2.com/tempo-therapeutics-raises-14-5-million-to-advance-regenerative-tissue-technology-toward-commercialization/amp/",
    "title": "Tempo Therapeutics Raises $14.5 Million To Advance Regenerative Tissue Technology Toward Commercialization - Pulse 2.0",
    "excerpt": "Tempo Therapeutics has closed an oversubscribed $14.5 million financing round to advance its Microporous Annealed Particle regenerative technology through potential regulatory clearance and commercialization. Galaxy Sirius Partners led the financing, with participation from Johnson & Johnson through Johnson & Johnson Innovation – JJDC, Gideon Strategic Partners, Mesa Verde Venture Partners, YK Bioventures and other new and existing investors. Tempo is developing synthetic biomaterials designed to help the body regenerate healthy, functional tissue. The company’s MAP technology is a flowable and porous biomaterial designed to conform to irregular tissue spaces and support cellular infiltration, vascularization and new tissue formation before gradually being replaced by the patient’s own tissue. The financing follows the publication of positive first-in-human clinical data and submission of a De Novo application to the FDA for Tempo’s lead product. Proceeds will support the surgical reconstruction program through potential regulatory clearance and commercialization while also funding clinical work around additional uses of MAP, including regenerative aesthetics. Tempo’s recently published randomized, controlled, multicenter study included 40 patients with full-thickness wounds following Mohs surgery for non-melanoma skin cancer. The study met its primary safety endpoint, with no...",
    "summary": "Johnson & Johnson, through its innovation arm JJDC, participated in a $14.5 million financing round for Tempo Therapeutics.",
    "planning": false,
    "confidence": 0.9,
    "published_at": "2026-09-19T12:22:36Z",
    "article_sentence": "Galaxy Sirius Partners led the financing, with participation from Johnson & Johnson through Johnson & Johnson Innovation – JJDC, Gideon Strategic Partners, Mesa Verde Venture Partners, YK Bioventures and other new and existing investors.",
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "Tempo Therapeutics",
    "related_company_domain": "tempotherapeutics.com"
  }
}

curl https://signals.autobound.ai/v1/signals/49d66914-0ee3-a1c3-cbaf-d4afb7dfda7e \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'